DMAC

MKT CAP:$339M

DiaMedica Therapeutics Inc.

Market Cap

$339M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$6.23-$1.70 (-21.47%)

Apr 23, 2026

Company Details

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phas...

CEO

Dietrich John Pauls

IPO Date

Aug 3, 2012

Website

www.diamedica.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$33M

EPS (Diluted)

-$0.70

Free Cash Flow

-$29M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 30, 2026

$0EPS -$0.70

Q4 2025

Mar 30, 2026

$0EPS -$0.17

Q3 2025

Nov 12, 2025

$0EPS -$0.17

Q2 2025

Aug 12, 2025

$0EPS -$0.18

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$4M
Q2 22	$0	-$6.0K	-$3M
Q3 22	$0	-$7.0K	-$3M
Q4 22	$0	$0	-$4M
Q1 23	$0	$0	-$6M
Q2 23	$0	$0	-$5M
Q3 23	$0	$0	-$5M
Q4 23	$0	-$8.0K	-$6M
Q1 24	$0	$0	-$6M
Q2 24	$0	$0	-$6M
Q3 24	$0	$0	-$7M
Q4 24	$0	-$11.0K	-$8M
Q1 25	$0	$0	-$8M
Q2 25	$0	$0	-$8M
Q3 25	$0	-$18.0K	-$9M
Q4 25	$0	-$14.0K	-$9M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$4M	-$4M
Q2 22	-$2M	-$3M
Q3 22	-$2M	-$2M
Q4 22	-$3M	-$3M
Q1 23	-$5M	-$5M
Q2 23	-$5M	-$5M
Q3 23	-$5M	-$5M
Q4 23	-$4M	-$4M
Q1 24	-$7M	-$7M
Q2 24	-$5M	-$5M
Q3 24	-$4M	-$4M
Q4 24	-$6M	-$6M
Q1 25	-$7M	-$7M
Q2 25	-$8M	-$8M
Q3 25	-$7M	-$7M
Q4 25	-$8M	-$8M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$6.0K
Q3 22	$43.0K
Q4 22	$32.0K
Q1 23	$7.0K
Q2 23	$4.0K
Q3 23	$10.0K
Q4 23	$3.0K
Q1 24	$9.0K
Q2 24	$0
Q3 24	$9.0K
Q4 24	$7.0K
Q1 25	$12.0K
Q2 25	$6.0K
Q3 25	$16.2K
Q4 25	$6.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-2.3%
Q2 22	—	-0.0%
Q3 22	—	-8.4%
Q4 22	—	+22.4%
Q1 23	—	+56.1%
Q2 23	—	+40.9%
Q3 23	—	+64.9%
Q4 23	—	+47.2%
Q1 24	—	+4.0%
Q2 24	—	+18.9%
Q3 24	—	+33.5%
Q4 24	—	+44.0%
Q1 25	—	+41.9%
Q2 25	—	+42.0%
Q3 25	—	+31.2%
Q4 25	—	+9.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$308.0K	—
Q2 22	$365.0K	—
Q3 22	$418.0K	—
Q4 22	$411.0K	—
Q1 23	$422.0K	—
Q2 23	$380.0K	—
Q3 23	$425.0K	—
Q4 23	$456.0K	—
Q1 24	$488.0K	—
Q2 24	$443.0K	—
Q3 24	$565.0K	—
Q4 24	$589.0K	—
Q1 25	$867.0K	—
Q2 25	$771.0K	—
Q3 25	$0	—
Q4 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$2M	$2M	—	—
Q2 22	$2M	—	—	$1M
Q3 22	$2M	—	—	$1M
Q4 22	$2M	$2M	$26.0K	—
Q1 23	$4M	$2M	$41.0K	—
Q2 23	$3M	$2M	—	—
Q3 23	$3M	$2M	—	—
Q4 23	$4M	—	—	$2M
Q1 24	$4M	$2M	$39.0K	—
Q2 24	$4M	$2M	—	—
Q3 24	$5M	$2M	—	—
Q4 24	$6M	—	—	$2M
Q1 25	$6M	$2M	$45.0K	—
Q2 25	$6M	$2M	—	—
Q3 25	$6M	—	—	$3M
Q4 25	$7M	$3M	—	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$3M	$38M	$41M
Q2 22	$3M	$35M	$38M
Q3 22	$3M	$33M	$36M
Q4 22	$5M	$29M	$34M
Q1 23	$2M	$27M	$29M
Q2 23	$6M	$35M	$40M
Q3 23	$2M	$44M	$46M
Q4 23	$5M	$48M	$53M
Q1 24	$2M	$44M	$47M
Q2 24	$14M	$40M	$54M
Q3 24	$4M	$46M	$50M
Q4 24	$3M	$41M	$44M
Q1 25	$3M	$34M	$36M
Q2 25	$4M	$26M	$30M
Q3 25	$3M	$52M	$55M
Q4 25	$16M	$44M	$60M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	26M	+38.9%	+40.9%
Q2 22	26M	0.0%	+40.8%
Q3 22	26M	0.0%	+38.9%
Q4 22	26M	0.0%	+38.9%
Q1 23	26M	+0.0%	+0.0%
Q2 23	27M	+3.3%	+3.3%
Q3 23	38M	+38.9%	+43.5%
Q4 23	38M	+0.0%	+43.5%
Q1 24	38M	0.0%	+43.5%
Q2 24	38M	+0.3%	+39.4%
Q3 24	43M	+12.3%	+12.7%
Q4 24	43M	+0.2%	+12.8%
Q1 25	43M	+0.1%	+12.9%
Q2 25	43M	+0.3%	+12.8%
Q3 25	50M	+15.5%	+16.1%
Q4 25	47M	-5.3%	+9.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	15
Q2 22	$0	15
Q3 22	$0	15
Q4 22	$0	16
Q1 23	$0	16
Q2 23	$0	16
Q3 23	$0	16
Q4 23	$0	19
Q1 24	$0	19
Q2 24	$0	19
Q3 24	$0	19
Q4 24	$0	28
Q1 25	$0	28
Q2 25	$0	28
Q3 25	$0	28
Q4 25	$0	35

Revenue / Employee